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Abstract: Extracellular vesicles (EVs), including exosomes, are membranous particles released by
cells into the extracellular space. They are involved in cell differentiation, tissue homeostasis, and
organ remodelling in virtually all tissues, including the central nervous system (CNS). They are
secreted by a range of cell types and via blood reaching other cells whose functioning they can modify
because they transport and deliver active molecules, such as proteins of various types and functions,
lipids, DNA, and miRNAs. Since they are relatively easy to isolate, exosomes can be characterized,
and their composition elucidated and manipulated by bioengineering techniques. Consequently,
exosomes appear as promising theranostics elements, applicable to accurately diagnosing pathological
conditions, and assessing prognosis and response to treatment in a variety of disorders. Likewise,
the characteristics and manageability of exosomes make them potential candidates for delivering
selected molecules, e.g., therapeutic drugs, to specific target tissues. All these possible applications are
pertinent to research in neurophysiology, as well as to the study of neurological disorders, including
CNS tumors, and autoimmune and neurodegenerative diseases. In this brief review, we discuss what
is known about the role and potential future applications of exosomes in the nervous system and its
diseases, focusing on cell–cell communication in physiology and pathology.
Keywords: exosomes; extracellular vesicles; nervous system; central nervous system; cell–cell
interaction; biomarkers; theranostics tools; neurological diseases
1. Exosomes, Microvesicles for Cell–Cell Communication and Tissue Homeostasis
Eukaryotic cells in multicellular organisms need to communicate with each other in order to
maintain tissue homeostasis and to respond to pathogens in the extracellular milieu. Generally, cells
exchange information through direct cell–cell contact or by secretion of soluble factors [1]. Mechanisms
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of intercellular interaction are known that involve the production and release of extracellular vesicles
(EVs). Cells interact and influence the extracellular environment and other cells in various ways,
for instance by releasing different types of EVs, which serve various functions depending on their
origin and molecular composition. EVs include a variety of nanoscale membranous vesicles that are
released by many cell types into the extracellular environment and can reach virtually all parts of the
body [2]. EVs carry molecules such as nucleic acids, proteins, and lipids to specific target cells and
can be classified according to their size, biogenesis, functions, and composition [3,4]. There are three
main types of EVs: (1) microvesicles (100–1000 nm in diameter); (2) apoptotic blebs (1000–5000 nm in
diameter); and exosomes (diameter 20–150 nm). The former two represent heterogeneous populations
of vesicles generated by outward budding of the plasma membrane. Exosomes instead are generated
by invagination of endosomal membranes and subsequent production of multivesicular bodies
(MVBs) [5,6]. Frequently, in the literature, the terms exosomes and EVs are used imprecisely, most
likely because a standardized, uniformed method for their isolation–characterization is not used
universally and, therefore, the results vary among laboratories. Nevertheless, because of the increasing
interest in EVs and because exosomes are currently the best characterized among them, in this review
we will focus on the latter.
It was initially thought that exosomes could be a mechanism for shedding the cytoplasm in
maturing sheep reticulocytes [7]. Later, it was demonstrated that exosomes are active players in
intercellular communication [8–11], originate in endosomes and are secreted by all cell types, including
neurons, under physiological and pathological conditions [12]. Exosomes are present in body fluids
such as blood; urine; breast milk; saliva; and cerebrospinal, bronchoalveolar lavage, ascitic, and
amniotic fluids [11,13–21].
Exosomes are released into the extracellular space after the merging of late endosomes with the
cell membrane. Previously, early endosomes become part of multivesicular bodies (MVBs), which
undergo a maturation process characterized by a gradual change in protein composition of the vesicles
(intraluminal vesicles, ILVs). During this maturation process, the vesicles that have accumulated
in the MVBs can follow three different pathways: (1) merge with the lysosomes, which leads to the
degradation of their protein cargo (e.g., in the case of signalling receptors); (2) constitute a temporary
storage compartment; and (3) blend with the plasma membrane, releasing exosomes. MVBs merge
with the plasma membrane, resulting in exocytosis of the vesicles contained in them so that the
vesicles’ membrane maintains the same topological orientation as the plasma–cell membrane [1,22,23].
The endosomal sorting complexes required for the transport machinery (constituted of the proteins
ESCRT-0, -I, -II, -III) is involved in exosome biogenesis and loading [24]. ESCRT-1 assists in the sorting
of the ubiquitinated cargo proteins at the endosome membrane and the ESCRT-associated protein
ALIX (apoptosis-linked gene 2-interacting protein X) can regulate this function [24,25].
The content of exosomes reflects that of the cell of origin and, consequently, there is interest in
characterizing it to obtain information on the cell of origin and the functions of exosomes, and to assess
the potential of exosomes as drug delivery tools. The composition of exosomes depends on parental
cell conditions, and includes lipids; proteins; and nucleic acids, such as DNA, non-coding RNA, rRNA
(ribosomal RNA) and miRNAs (microRNAs) [26].
The lipid composition of exosomes is characteristic and includes cholesterol, phosphatidylcholine,
sphingolipid ceramide, and sphingomyelin that probably stabilize the exosomal bilayer membrane
and maintain its integrity in the extracellular milieu [27]. The sphingolipid ceramide plays a key role
in the budding of exosomes [28].
Various classes of proteins are found in exosomes, such as proteins involved in the vesicles’
trafficking, cell surface receptors, and proteins involved in endocytic pathways (GTPases; annexins;
flotillin; endosomal sorting complex required for transport, ESCRT, such as Alix; tumor susceptibility
gene 101, TSG101; integrin; and a number of tetraspanins such as CD9, CD53, CD63, CD81, and CD82,
depending on the cell of origin). Also, in exosomes are proteins with specific post-translational
modifications (PTMs) [29,30], and proteins that are important in long-distance communication,
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such as cytokines [31], hormones [32], growth and transcription factors [33], and heat-shock proteins
(HSPs) [10,30,34,35].
The presence of mRNA [36] and miRNA [37–41] in exosomes indicates activity in the regulation
of gene expression in both recipient and donor cells, suggesting horizontal transfer of genetic
information [42].
Depending on the parental cells and their contents, exosomes may have many different functions.
They are involved in cell-to-cell information transfer [43], immune response [44], inflammation [45],
coagulation [46], stem cell activation [47], and programmed cell death [48]. Exosomes can participate
in cellular responses against stress [49]. It has been shown that exposing B-cell lines to heat stress
results in a marked increase of HSPs in exosomes and in an increase in the quantity of exosomes
produced [10,11,30,49–51].
Since exosomes can mediate transfer of molecules, it is very likely that they play a key role in
intercellular interactions and in the maintenance of tissue homeostasis [52,53]. For example, exosomes
play physiological roles in neuronal development, transmission of electrical impulse, and regeneration,
and, consequently, can play a pathogenic role in neurological disease [54].
2. Nervous System Cells and Tissues: An Overview
The nervous system, composed by the central nervous system (CNS), and the peripheral nervous
system (PNS), is implicated in the communication with both the external and internal environment of
the organism by responding to chemical and physical stimuli [55].
The main cell types found in the nervous tissue are neurons, or nerve cells, that have the ability to
rapidly receive and transmit impulses to and from different parts of the body, and neuroglia, or glial
cells, which assist in the propagation of the nerve impulses and provide nutrients to the neurons
(Figure 1). Both neurons and neuroglia cells develop from the dorsal ectoderm of the early embryo but
different types of them can be distinguished, which are characteristic of the CNS or PNS (Figure 1).
Overall, these cells are responsible for most of the functional features of nervous tissue [56]. Since
exosomes can be specific for the cell type that produce them, we briefly recapitulate the main features
of the cells that constitute the nervous tissue and that, when their homeostasis is affected, can be
implicated in the pathogenesis of nervous system diseases.
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Despite the fact that neurons can be specialized and differ in a variety of features, they all share
several characteristics. The key function of neurons is to communicate between them and with other
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cell types. When the nerve impulses travel along the axon in the form of an action potential, the vesicles
at the axon terminal, which contain neurotransmitters or neuromodulators, release their content by
exocytosis. These signals between neurons are passed via specialized connections called synapses [57],
in which either the axon terminal or an en passant bouton (a type of terminal located along the
length of the axon) of one cell contacts another neuron’s dendrite, soma or less commonly, axon [57].
The chemical transmitters travel across the synaptic cleft to reach receptors on the postsynaptic cell.
According to the neuron doctrine founded by Ramón y Cajal and then supported by subsequent
investigators, this seems an appropriate description for most synapses in vertebrates and invertebrates,
but several studies and new technology applications, such as electron microscopy, have pointed out
the existence within CNS of new synapses, called mix synapses and synapses à distance, where the
axon and the dendrites appear to be exchanging their roles. It could lead to reform of the neuron
primary doctrine and render it more pliable [58]. In the last decade, in vitro studies demonstrated
that, depending on synaptic activity, neurons release exosomes that can be retaken by other neurons
suggesting a novel way for inter-neuronal communication [59].
The term glia derives from the ancient Greek word “glía” meaning “glue” in English, and may
suggest a passive type of cell; however, glial cells are active, providing support and nutrition to the
neurons, form myelin, and, by insulating axons, speed up electrical communication [60]. A major
distinction between glia and neurons is that glia do not participate directly in synaptic interactions
and electrical signaling. However, emerging evidence suggests that glia, particularly astrocytes, are
involved in the formation of synapses and in modulating synaptic function through bidirectional
communication with neurons, both during development and in adulthood [60].
For many years it has been argued that the number of glial cells in the brain was significantly
higher than neurons, but recent work has revealed that neurons and glia are almost equal in number
in the human cortex [61–63]. However, it is possible that the proportions of neurons and glial cells
vary in different brain areas [64].
Neuroglia of the CNS can be divided into macroglia and microglia (Figure 1). The macroglia
includes oligodendrocytes, astrocytes, and ependymoglial cells that originate from the ectoderm, while
the microglial cells derive from the yolk sac and they are found in the CNS during early embryonic
development [65].
Spinal cord and brain contain different subclasses of oligodendrocytes (OLGs) which derive from
multiple sources [66] (Figure 1). OLGs provide a lipid-based insulation and, thus, increase the speed at
which the action potential can travel in the axon.
Within the oligodendrocyte linage, there exist the NG2-glia/oligodendrocyte cells. They are
characterized by the presence on their surface of chondroitin sulfate proteoglycan and are considered an
independent glial population, but their function in the adult brain is not yet fully established. NG2-glia
maintains the physiological and homeostatic conditions of the nervous tissue generating mature
myelinating oligodendrocytes; furthermore, it forms synapses with neurons of the hippocampus and
probably in other parts of the brain, too [67]. Notably, NG2-glial cells have the ability to receive signals
without creating or propagating action potentials [67].
The astrocytes are supportive glial cells in neural tissue with a star-like appearance because of
their elaborate cytoplasmic processes [68–70].
Astrocytes play a role in a variety of complex and essential functions in the healthy CNS,
such as the maintenance of water and ion homeostasis and blood–brain barrier (BBB) integrity, as
well as participation in tripartite synapses, all of which make astrocytes active actors in synaptic
context [60,71]. Furthermore, astrocytes can inhibit or enhance overall levels of neuronal activity by
releasing neurotransmitters. For many years astrocytes were classified into just two types, but now,
according to their structure and anatomic location, up to four major classes of GFAP+ astrocytes are
known to occur in the human brain: interlaminar astrocytes are located in layers I and II of the cortex;
protoplasmic astrocytes reside in layers III and IV; astrocytes in varicose projections in layers V and VI;
and fibrous astrocytes in white matter [72].
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In the functional regulation of the microenvironment, astrocytes and oligodendrocytes release
EVs, in order to facilitate the cell–cell communication and the activity of target cells [73–75].
The CNS macroglia cells are the ependymoglial cells derived from the neuroepithelium. They
populate the interface between the brain parenchyma and the cavity of the ventricles in the CNS, and
the central canal of the spinal cord. Macroglial cells appear with various shapes from cuboidal to
columnar with cilia and microvilli on the apical surfaces to enhance absorbance and circulation of
cerebral spinal fluid (CSF).
Ependymoglial cells are of three types: ependymocytes, which make contact with the basal lamina
labyrinths (remnants of embryonic blood vessels) and with the ventricles where they contribute to the
CSF movement [76,77]; choroid plexus epithelial cells, which secrete CSF; tanycytes, highly specialized
ependymal cells that form a blood–CSF barrier and blood–CSF homeostasis [78]. Despite their role
in CSF-barrier homeostasis regulation, there is not yet evidence for the exosomes’ secretion by the
ependymal cells. However, they can be isolated by CSF [13,79], thus suggesting that they pass this
barrier by still unknown mechanisms.
Differently from the previously described cells of the nervous system, the microglial cells originate
from mesodermal hematopoietic cells that in mammals come from the yolk sac [80,81]. They serve
as innate immunity elements of the CNS independently of blood cells. With self-renewal ability they
act as unique tissue-resident macrophages involved in immune reactions and inflammatory diseases
(Figure 1) [82].
To define the microglial cells just as macrophages would be an oversimplification because,
in addition to their role in defending against bacterial and viral infections, they play a crucial role in the
maturation of neural circuits by their “synaptic pruning” function [83]; they also produce brain-derived
neurotrophic factor (BDNF) to survey mature neurons, mediate synapses, and remove myelin debris
by phagocytosis [83,84].
Microglial cells have a great morphological plasticity and with their highly motile processes
without moving their bodies constantly explore their environment. By screening the brain parenchyma
these cells rapidly search for pathogens, signs of injury, or homeostatic disturbances [85,86]. Finally,
the regulation of the neuronal plasticity by microglia may occur also by EVs releasing that have been
reported implicated in the increase of neuronal synaptic activity in vitro and in vivo [75].
The functions of the nervous system and immune system are often considered independent
from one another, however, this is a simplistic distinction, because in the regulation of the organism
homeostasis, they are in constant communication [87,88]. This relationship was demonstrated long ago
by the description of the association between peripheral neurons and mast cells, that are implicated
in neuroinflammation [89]. The communication between neurons and mast-cells occurs through to
several paracrine signals and also synapses, but the full understanding of this relation may open
important scenarios pertaining to the onset of neuroinflammatory diseases [90].
In the PNS there are two types of neuroglia: Schwann cells (SCs) that myelinate axons; and satellite
glial cells, that regulate nutrient and neurotransmitter levels in ganglia (Figure 1).
SCs are recognized as the PNS counterparts of the oligodendrocytes in CNS, as they are involved
in the neuromuscular synapse formation and in wrapping myelin around neuronal axons to form
the myelin sheath. This SC activity promotes the efficient and energy low-cost propagation of axon
potentials via saltatory conduction by maintaining internodal—each myelin segment is flanked by
unmyelinated nodes of Ranvier–myelin sheath thickness and length relative to the diameter of the
corresponding axon [91]. SCs can perform many unique functions, including duplicating the roles of
the astrocytes and microglia as seen in the central nervous system (CNS) [92]. The terminal Schwann
cells (tSCs, also called non-myelinating SCs or perisynaptic SCs) have a role in “synapse elimination”
during development and, throughout adult life [93], effect the regeneration of injured peripheral
motor axons [94]. Schwann cells provide trophic support and transfer materials to damaged axons
via exosomes [95]. Furthermore, they maintain developing synapses, and participate in synaptic
pruning [96,97].
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Satellite glial cells (SGCs) have the same origin as Schwann cells. Sensory ganglia of the dorsal
roots of the spinal cord are composed of afferent neurons without a myelin sheath but lined by SGCs
and connective tissue cells.
SGCs share many features with astrocytes, like the expression of glutamine synthetase and
various neurotransmitter transporters. They cover axon terminals that make synaptic contacts on,
or near, the neuronal somata, wrap around dendrites that emerge from neuronal somata to control
the microenvironment and, similarly to astrocytes, influence synaptic transmission [98,99]. SGCs
can be considered a substitute of the lacking BBB in sensory ganglia and have been shown to have
phagocytic activity [98]. The role in microenvironment regulation and inflammation modulation by
SGCs exosomes remains unknown [100,101].
The Possible Two-Way Journey of Exosomes Released by CNS Cells
The roles of exosomes in the CNS may be as follows: on the one hand, they can be
active components necessary for the development and protection of the CNS under physiological
conditions [12,102,103], whereas on the other hand, they may participate in pathogenesis by favoring
some neurodegenerative and neuroinflammatory phenomena, as suggested, for example, by the fact
that microglial exosomes are found in high concentrations in patients with Alzheimer’s disease (AD)
and exosomes produced by oligodendroglioma cells induce neuronal death [104].
Since exosomes are involved both in healthy and pathogenic state of CNS, it is not surprising that
these vesicles are released by most of the CNS cells, including neurons, microglia, oligodendrocytes,
astrocytes, and neural embryonic stem cells, Figure 2 [105,106]. Questions of great interest are whether
these exosomes have the ability to cross the BBB and hematoliquor barrier; and whether they come
from the CNS to the periphery, or they come from the periphery to the SNC in normal physiological
and in pathological conditions.
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Figure 2. Schematic representation of the nervous tissue and exosome traffic. Some of the cells
presented in Figure 1 are here seen in the central nervous tissue along with a blood vessel. Also present
are epithelial cells lining the inside of the blood vessel, the blood–brain barrier (BBB) separating the
lumen of the vessel from the nervous tissue, and exosomes secreted by the four types of nervous cells
shown. Exosomes follow different routes, as indicated by double parallel arrows, from one cell to
another or through the BBB they gain the general circulation and reach distant targets. Conversely,
exosomes can traverse the BBB from inside the vessel into the nervous tissue and reach any of the
nervous cell types in it.
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Cells from malignant gliomas, i.e., primary tumors that arise from neuroglial stem or progenitor
cells, produce and release in circulation exosomes with potential to induce malignant transformation
of normal cells [107]. It has been reported that with a immunomagnetic exosome-RNA (iMER) analysis
platform, it is possible to enrich glioblastoma (GBM)-derived exosomes from blood of patients, and
compare the exosomes’ GBM-derived mRNA profiles against those of their cells of origin [108].
In amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), FTD-ALS, tauopathies,
and Parkinson’s (PD) and Alzheimer’s (AD) diseases, exosomes migrate via blood and CSF carrying
misfolded proteins or pro-inflammatory molecules [109–111].
Modified rabies virus glycoprotein (RVG)-targeted EVs were used to transport siRNA across
BBB [112], that can specifically inhibit target genes in the brain [112]. Modified blood-borne
macrophages were used to carry antioxidant proteins called nanozymes [113]. It was demonstrated
that the therapeutic protein crossed the BBB and it was suggested that one of the mechanisms used by
macrophages to transfer nanozymes to target recipient cells was the release of exosomes [113].
Furthermore, it was demonstrated that the uptake of EVs by neurons in vitro (neuronal rat adrenal
pheochromocytoma cell line, PC12 cells) and in vivo neurons and microglial cells of mouse, is more
efficient than that of other traditional carriers, i.e., liposomes [114].
3. Exosome-Mediated Cross-Talk between Cells in Neurogenesis and Neurohomeostasis
The development and maintenance of neuronal circuits in the CNS requires a complex series
of events involving coordinated short- and long-distance communication between numerous cell
types. Neurons interact continuously with each other and with glial cells through electrical signals
and through chemical mediators. In chemical synapses, more common than electrical synapses in the
human CNS, the transmission of signals is carried out by chemical mediators, named neurotransmitters.
The neurotransmitters are secreted by the pre-synaptic cells inside vesicles that reach the post-synaptic
cells, where multiple downstream events, both electric and molecular, are triggered by binding of
the neurotransmitter to specific receptors [115]. In view of these phenomena, it is not surprising that
neuronal cells may also release different types of EVs, such as exosomes that could have an impact
on synaptic activity, in neurogenesis, and in the overall regulation of neurological activities. In this
section, we will briefly describe known physiological functions of exosomes in CNS (Figure 2).
CNS neurons secrete exosomes to control the complex and coordinated communication among
them and, with astrocytes and microglia, thus exosomes mediate a generalized cross-talk, in order to
regulate neuronal regeneration and synaptic functions in development and adult life [116,117].
To the best of our knowledge, the first report regarding exosomes produced by neural cells is
relatively recent. Glial cell lines overexpressing a prion protein (PrPsc) released exosomes as a way
to spread the PrPsc and, these exosomes bearing PrPsc were infectious, contributing to the spread
of prions throughout different areas of CNS and the whole organism [118]. Successively, it has been
shown that neurons may exploit the exosome pathway to maintain homeostasis and regulate cell–cell
interactions, for instance, as a way to discard unwanted proteins or degraded products. This hypothesis
has been proposed to explain how primary cortical neurones in culture release exosomes in a controlled
manner, while their composition is regulated by cell depolarisation [12]. The exosomes released are
captured by neighbouring cells and the exosomal cargoes elicit distinct downstream events [12]. Other
studies on exosome secretion from neurons have been conducted with embryonic neurons in culture.
It was hypothesized that exosome release is a key mechanism during neurogenesis that seems to be
necessary for protein removal, and is a consequence of the fusion of late endosomes with lysosomes,
during the neurite elongation [119–121]. In addition, exosomes released from neurons may contribute
to the local elimination of receptors at synapses undergoing plastic changes and escaping from
the vesicles retrograde transport through the axon [59,122]. During neuronal remodelling, exosomes
released by neurons could have a role in synapse elimination, stimulating microglial phagocytosis [123].
Furthermore, as the cytoplasmic calcium levels increase, MVBs’ fusion to the plasma membrane occurs
and is followed the secretion of exosomes. This seems to be a mechanism used by neurons to detect the
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strength of the excitatory synapses and adjust them, a mechanism that might be necessary to regulate
the functioning of synapses and maintain homeostasis during neuronal plastic changes [124]. In order
to regulate extracellular glutamate levels and modulate synaptic activation, neurons communicate with
astrocytes by secreting exosomes, which contain several regulatory molecules that are internalized by
astrocytes, thus eliciting a neuronal-dependent modification of the expression of glutamate transporters
(e.g., GLT1) [125]. Multiple interactions between glia-derived exosomes and neurons (Figure 2), also
suggest a role of these vesicles in neural circuit development and maintenance, by promoting neurite
outgrowth from hippocampal neurons and increased survival of cortical neurons [74].
Microglia-derived exosomes can modulate neuronal activity also via enhanced sphingolipid
metabolism [75]. Inflammatory microglia-derived exosomes transfer their miRNA cargo (miR-146a-5p)
to neurons determining the loss of excitatory synapses, suggesting a role during brain inflammation,
probably silencing key synaptic genes [126].
In CNS, oligodendrocyte progenitor cells secrete exosome-like vesicles carrying myelin proteolipid
protein (PLP), 2’3’-cyclic-nucleotide-phosphodiesterase (CNP), myelin basic protein (MBP), and myelin
oligodendrocyte glycoprotein (MOG) [127]. The oligodendrocyte-derived exosomes may contribute
to balanced production of myelin proteins and lipids and, therefore, these exosomes may be part
of a mechanism of formation and control of myelin membrane biogenesis [103,127]. In adult CNS,
during cell renewal and tissue regeneration, oligodendrocytes use the exosomal pathway to induce the
microglia toward degradation of oligodendroglial membrane by macropinocytosis, without immune
system activation [128]. The concomitant transfer of antigens from oligodendrocytes to microglia could
be implicated in the pathogenesis of autoimmune conditions of the CNS.
The fact that exosomes can reach the circulation and the CSF makes these vesicles likely means of
long-distance communication and transport for bioactive molecules to be delivered to selected targets.
Because of their capability to cross the BBB [129,130], and because their content reflects faithfully that
of the cell of origin, circulating exosomes can reveal the status of the tissue from which they come and,
thereby, provide an accurate means for early, minimally invasive (peripheral blood drawing) diagnosis
of neurological diseases [22,41,131] (Figure 2).
On the other side of the matter, peripheral organs can influence the functions of CNS through
exosomes [132,133]. The gut–brain axis is an example of an unconventional system of communication
between the intestinal mucosa and brain, different from peripheral nerves.
The intestinal microbiota-derived EVs (named outer membrane vesicles, OMVs) can also enter the
systemic circulation and pass through the BBB, inducing neuroinflammation that could be implicated
in the pathogenesis of depressive disorders [134] and affect the BBB permeability [135]. The modality
by which exosomes cross the BBB still remains unclear; however, this characteristic makes exosomes
good candidates as biomarkers for diagnostics purposes, and for delivering therapeutic agents to
neural tissues.
4. Role of Exosomes in Nervous System Pathogenesis and Theranostics
Progress in the medical sciences has been steady over the last few decades, encompassing the
discovery of etiological agents, elucidation of pathogenic mechanisms, and development of new
diagnostic techniques and therapeutic strategies. One of the major obstacles to improving patient
management has been the heterogeneity of any given disease, which varies from patient to patient.
Thus, personalized medicine has emerged to develop means of diagnosis and treatment for the
management of each patient in accordance with its specific characteristics. Theranostics is one
advance in this direction that also aims at combining diagnostic and therapeutic capabilities in a single
agent [136]. Examples of theranostics agents are nanoparticles such as liposomes, polymers, micelles,
solid (lipid) nanoparticles, antibodies, and now also exosomes, that can be modified and improved
with drugs and imaging agents [137]. Nanoparticles have the ability to interact in a site-specific manner
with biomolecules present on the cell membrane surface or inside the cell, co-delivering therapeutic
and diagnostic/monitoring agents at the same time into diseased tissue. Appropriate targeting can be
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implemented using diverse strategies; for instance, to identify a cancer biomarker aberrantly expressed
on the cell surface [138]. Theranostics has manifold advantages: (1) it can be carried out before, after,
or during treatment; (2) the specific localization of the theranostics agents on a defined target reduces,
or may even eliminate, possible side effects and can also help identify patients with susceptibility to
side effects; (3) allows tumor homing: the nanometric size of the particles and the typical irregularity
of blood vessels with dilated fenestrations, allow the extravasation and accumulation of nanoparticles
into the tumor mass, improving the enhanced-permeability-and-retention (EPR) effect; and (4) it
allows the achievement of a more effective individualized therapy for various diseases [139,140].
Theranostics is viewed as a significant step forward in non-invasive or minimally invasive treatment
modalities with potential to accelerate drug development. However, theranostics has limitations in
what pertains, for example, to the limited quantities of the therapeutic agent that can be delivered to the
site where it is needed, the possibility of inducing immune reactions against the agent, manufacturing
difficulties during nanoparticle production, and the need of elimination of toxic metabolites that
might be generated during production and/or administration. In this regard, the biocompatibility,
biodegradability, and toxicity of the materials used to prepare the theranostics agents and the
pharmacokinetic and pharmacodynamic parameters of the compounds used have to be carefully
evaluated before clinical use. In summary, the balance between benefits and disadvantages in each
case must be critically assessed.
As described earlier, exosomes derived from different nervous system cells contain specific
molecules or cell markers, e.g., oligodendrocyte-derived exosomes contain proteins of the myelin
sheath; neuronal exosomes contain cell-adhesion proteins and receptor subunits; microglial-derived
exosomes carry peptidases and cytokines. This suggests that exosomes have the ability to regulate
and maintain functional cell homeostasis during health and under disease conditions. But on the
other hand, exosomes can favor the disease mechanism rather than stop it, when they carry and
deliver pathogenic molecules from the cell of their origin. This type of pathogenic role of exosomes
has been observed in neuronal disorders with misfolded proteins (neurodegenerative, autoimmune,
neuroinflammatory conditions), as will be discussed later.
4.1. Overview of CNS Disorders
Neurologic disorders are numerous and diverse and can be caused by a variety of etiologic agents
with many of the disorders being the consequence of the convergence of more than one etiopathogenic
factor. An important group of neurological disorders are inherited, i.e., a mutated gene, or group of
mutated genes are present in the genome of an individual which transmits it to its descendants. Some of
these mutations are now well characterized [141–143]. However, the pathogenetic mechanisms of many
of these genetic diseases are still poorly understood. Other disorders are caused by sporadic random
gene mutations and are not heritable. Genetic polymorphisms; old age; gender; poor education,
endocrine, immune and metabolic conditions; oxidative stress; inflammation; stroke; hypertension;
diabetes; smoking; head trauma; depression; infection; tumors; vitamin deficiencies; and exposure to
certain chemicals are considered risk factors that may contribute to the development of neurological
diseases, including AD, PD and ALS, in individuals that are probably genetically pre-disposed [144].
Some gene mutations, random or inherited, affect development and functioning of the nervous system,
leading to neuropathies, myopathies, epilepsies, ataxias, and degenerative disorders of the brain
and spinal cord (Table 1, Figure 3) [145]. In what pertains to the etiology of nervous system tumors,
there are still doubts and obscure situations: although genes associated with pathogenesis have been
identified, other risk factors and comorbidities seem to also play determinant roles [146]. This situation
is reflected in the classification of neurological disorders, which are encompassed in various large
groups and subgroups, as summarized in Table 1 and in Figure 3. Because of the multifactorial
mode of etiology, many neurological disorders can be assigned to more than one group or subgroup.
Also, neurological disorders can be classified considering the location of the characteristic anatomic
pathology, symptoms and signs, outcome, and other parameters.
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Table 1. Major neurological diseases and their main etiopathogenic features.
Disease
Main Etiopathogenic Feature b
Genetic Autoim-Mune Inflam-Matory Degen r-Ative Vascular Tumoral PGV a
Multiple Sclerosis x x x
Alzheimer’s x x x x
Parkinson’s x x x
Amyotrophic
Lateral Sclerosis x x x
Ependymoma x x
Medulloblastoma x x x
Diffuse intrinsic
pontine glioma x x
Glioblastoma x x x
Malignant
eripheral nerve
sheath tumor
x x x
a PGV, possible genetic variants. b The symbol “x” in table cell indicates that the etiopathogenic feature mentioned
at the top of the column is present in the corresponding disease mentioned in the left-most column.
The n vous system cells, Figure 1, can be the target of adaptive cellular and humoral immune
respons s, causing autoimmunity-induced damage [147]. Autoimmunity disorders involving the
nervous system hav been exte ively investigated over the last few decades as in e case of multiple
sclerosis (MS), which is characterized by inflammation with anti-myelin pecific antibo ies causing
demy lination and eurodegeneration [148].
Neuroinflammatory disorders often include cases also classified within other groups.
Neuroinflammation occurs as a direct response of the glial cells against injury, microbial infection,
chemical substances, autoimmunity, or neurodegeneration of nervous tissue, but when the activation
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of microglial or macroglial cells becomes aberrant it can trigger acute inflammatory responses that
can progress toward chronicity and have serious pathogenic consequences. Chronic inflammation
is typically associated with some neurodegenerative diseases such as AD and PD. These and
other disorders, for instance MS and ALS, differ in pathophysiology and can cause memory and
cognitive impairments or affect a person’s ability to move, speak, and breathe. The outcome of a
neurodegeneration is the loss of structural and functional neuronal integrity. Since there are several
types of neurons and glial cells (Figure 1), their impairment causes a range of different symptoms
and signs.
Neurovascular diseases, owing to defects of blood vessels supplying blood to CNS, can increase
the risk of stroke. These neurovascular deficits are involved in pathogenic mechanisms in various
neurodegenerative diseases, as for instance in AD [149].
Tumors are benign and malignant neoplasias of the CNS, PNS, autonomic nervous system,
cranial nerves, and meninges (Table 1 and Figure 3). Genomic abnormalities can lead to glioblastoma,
ependymomas, medulloblastomas, and diffuse intrinsic pontine gliomas. Malignant peripheral nerve
sheath tumors (MPNSTs) are rare Schwann cell-derived neoplasms that can occur in individuals with
autosomal dominant tumor susceptibility syndrome neurofibromatosis type 1 (NF1) [150].
4.2. Exosomes in Neurological Disorders
Studies on exosomes have contributed to increasing our current understanding of the pathogenesis
of neurodegenerative disease. Since exosomal proteins were found accumulated in amyloid plaques in
the brain of AD patients [151], the involvement of exosomes in AD pathogenesis deserves investigation.
Secretion of exosomes may remove misfolded and/or aggregated proteins and transfer them to
neighboring cells and, thereby, perpetuate the disease process. In vitro and in vivo experiments
have confirmed that exosomes from neuronal cells contain precursors of amyloidogenic proteins
and enzymes for the maturation of precursors [152–155]. The role of exosomes is not yet clear, but
a possibility is that they could promote the spreading of beta-amyloid peptides and/or assist in the
removal of neurotoxic beta-amyloid from cells [152,153].
The likelihood of exosome involvement in AD pathogenesis was also suggested by the finding of
hyperphosphorylated tau protein in exosomes from neural tissue in culture and in human CSF [152].
Tau protein aberrantly accumulates in AD and, in this regard, microglial cells may participate in
spreading tau protein through various brain regions by releasing exosomes as carriers [152,153].
Hyperphosphorylated tau protein in exosomes from transgenic mice would indicate that PTMs could
enhance the abnormal process of tau formation and the spreading by exosomes [131,156]. In fact
protein phosphorylation could be a signal required for their release by exosomes [157]. Exosomes may
propagate tauopathies and, in AD, contribute to cognitive loss.
Currently, it is possible to diagnose AD when the disease is already established, e.g., when
the patient has already developed dementia. The previous stages often remain asymptomatic,
and these are the stages in which the patient could benefit most from treatment. Therefore, some
sort of early diagnostic procedure is needed and, for this purpose, exosomes could be considered
potentially useful biomarkers. Exosomes could act as Aβ scavengers binding Aβ to their surface
and, subsequently, microglial cells would internalize “charged exosomes” and process them for
degradation [158,159]. Consequently, exosomes derived from human adipose tissue-stem cells have
been proposed for therapeutic degradation of Aβ plaques [160]. AD is associated also with chronic
inflammatory responses. Microglia and astrocytes release inflammatory cytokines, and free radicals
and oxidative stress molecules are present in the affected brain areas. As previously mentioned,
Aβ is packaged into exosomes and the spreading from cell to cell and the promotion of amyloid
plaque formation can initiate an inflammatory cascade [159]. Exosomes with the transactive response
binding protein-43 (TDP43) are markers of amyotrophic lateral sclerosis and frontotemporal lobar
degeneration [161]. Neuronal cells, but not astrocytes or microglia, release in vitro exosomes with the
TDP43 full-length protein or its C-terminal fragments, both of which have been found in the brain
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of ALS patients [161,162]. Similarly to the transportation of protein tau in AD via exosomes with
the propagation of tauopathy (discussed earlier), the release of TDP43 facilitates the progression of
proteinopathy, neuroinflammation, and neurodegeneration [163]. In PD, alfa-synuclein aggregation
is the pathological marker. This presynaptic neuronal protein has been shown to be secreted via
exosomes and transferred to other normal cells [163,164], largely neurons and astrocytes, in which it
had toxic effects causing death of the recipient cells [165,166].
Abnormalities in miRNA molecules are found in inflammatory cell populations or pathological
samples of autoimmune disease [167]. It was demonstrated that exosomes carrying miRNAs can
affect the recipient neural cells and dysregulate gene expression [165]. Almost 100 miRNAs have been
found dysregulated in various affected tissue including brain, blood, and CSF of multiple sclerosis
patients [168]. miRNA expression profiles in MS-derived exosomes compared to exosomes derived
from healthy donors showed an overabundance of certain miRNAs, which were able to reduce the
frequency of immune cells via inhibition of naïve-cell differentiation. Therefore, altered miRNA
expression may play a role in pathogenesis of multiple sclerosis [168]. Exosome carrying miR-29b
can affect neuronal function in HIV patients by suppressing the expression of the neuroprotective
protein platelet-derived growth factor (PDGF)-B expression [169]. Also, in another infectious
neurodegenerative disorder, prion disease, it has been demonstrated an alteration of exosomal miRNAs
and, it has also been shown that prion protein scrapie (PrPSc) in neuronal exosomes can be passed to
other cells via the exosomes and, thereby, infect neuronal and non-neuronal cells [118].
Tumor cells, derived from primary brain tumours or from metastases, use exosomes as packages
to spread proteins and other molecules associated with malignancy [41,170]. Exosomes with their cargo
would participate in the modulation of the tumor microenvironment, for instance by regulation of
gene expression in the target cells and the functioning of the immune system, creating a pro-metastatic
niche [171]. Tumor cell-derived exosomes can cross the BBB, which enhances tumor dissemination.
This capability of tumor-derived exosomes to influence their environment has been demonstrated
by showing that the exosomal microRNAs secreted by astrocytes target and inhibit the PTEN tumor
suppressor gene expression in brain tumor cells, leading to enhanced oncogenicity [172]. Several
findings confirmed the role of the brain tumor-derived exosomes in modulating immune functions
by facilitating the induction of immunosuppressed phenotypes that favour the immune escape by
means of their cargo of molecular mediators [158,159,173]. Moreover, glioblastoma-derived exosomes
increase angiogenesis, which promotes tumor growth [174–176] and may support tumor dissemination
also through the BBB [177]. Exosome-bearing tumorigenic mediators released by neuronal malignant
cells have been isolated from serum of glioblastoma patients [174,178].
The current diagnostic approaches for most neurological disorders are limited to evaluation of
clinical symptoms and radiologic signs. Consequently, the diagnosis can be tardive and treatment often
produces negligible benefits. Therefore, it is necessary to find biomarkers that can be measured with
minimally invasive procedures if progress in early diagnosis and reliable and timely assessment of
response to treatment are to be achieved. Within this context, exosomes appear as suitable biomarker
candidates as the key specimens of liquid biopsies. Efforts should be made to standardize assays with
high specificity and sensitivity that would extract as much clinically relevant information as possible
from exosomes. This approach is promising, considering that exosomes are a showcase of molecules
present in their cells of origin.
4.3. Exosomes as Potential Therapeutic Tools
Some properties of exosomes make them, in principle, convenient for use as drug carriers for
delivery to the CNS. For example, exosomes can cross physiological barriers and can interact with
plasma-cell membranes, which may eventually lead to their penetration into target cells. Current
knowledge suggests that exosomes may have advantages in comparison with other drug delivery
agents such as liposomes, for example, in what concerns safety and selectivity, but more research is
needed to determine their practical value in clinics. Some of these issues are discussed below.
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In the last few years, research efforts have been focused on the manipulation of the exosomes’
content and their targeting to the CNS pathological sites for treating specific pathologies. The potential
application of exosomes and EV in general, as therapeutic tools, has led to the development of new and
advantageous therapies, particularly for brain tumors. Illustrative examples pertain to exosomes from
bone marrow and mesenchymal stem cells (MSCs) [179] that were re-engineered to carry therapeutic
drugs or other therapeutic molecules to diseased brain regions [180–182]. In one of the first studies,
in a zebrafish model, endothelial cell-derived exosomes loaded with doxorubicin had the ability
to pass through the BBB and reach brain tissue [180]. In other models, it has been found how the
engineered exosomes enhanced the anti-tumor properties of immune cells [183] and could confer drug
sensitivity [184,185].
In an animal experimental model of stroke, it has been shown that the intravenous administration
of MSC-derived exosomes enhanced neurite remodelling, neurogenesis, and angiogenesis, leading
to functional recovery [186]. The effect of neuronal damage recovery of MSC-derived exosomes was
demonstrated also in a model of spinal cord injury, in which the beneficial effect was probably mediated
by the transfer of miRNA-133b [187]. Mouse models have also been used in exosome-based therapies
targeting AD. Exosomes were loaded by electroporation with exogenous siRNA and engineered to
expose a brain-specific peptide and were delivered through the BBB [114]. This approach resulted in
a significant and dose-dependent knockdown of the mRNA and protein for BACE1, a protease that
produces N-terminal cleavage of amyloid precursor proteins that lead to Aβ aggregation [112].
In what pertains to the exosome-based strategies for the treatment of PD, the engineering of
exosomes by electroporation with catalase can be mentioned [114]. In a mouse model of neuronal
inflammation, intranasal administration of the engineered exosomes allowed them to interact with the
target neighbouring neurons and deliver the antioxidant activity of catalase into these cells [114].
In a brain ischemia mouse model, engineered exosomes loaded with curcumin reached the
target brain lesion after intravenous administration, supressing inflammation and apoptosis [188].
The efficiency of exosomes in passing through the BBB and in delivering a cargo protein was also
demonstrated in another in vivo model [189]. Exosomes from naïve macrophages interacted with
endothelial cells of microvessels in the BBB via native surface receptors.
The possible toxicity of exosomal preparations and the side effects of their administration in
neuronal tissue are still to be explored further and various technical hurdles need to be overcome.
However, exosomes have a great potential to be part of a versatile strategy to treat neurological
disorders for all the reasons discussed above, such as the requirement of minimally invasive techniques,
low immunogenicity, and ability to cross the BBB and reach the target pathological cells.
5. Conclusions
Incidence of CNS disorders is increasing worldwide, but no parallel progress in prevention and
treatment occurs [190]. Novel treatment strategies based on the use of exosomes may help correct
this deficiency and improve patient management. The reasons for the growing interest in exosomes
as theranostics tools for CNS disorders, can be attributed to their characteristics and may be listed
as follows: (1) the possibility of using exosomes as biomarkers, thus providing information about
the status of the CNS; (2) exosomes are able to transverse the BBB; (3) they can be collected and
administered with minimally invasive methods (e.g., peripheral blood and/or intranasal delivery);
(4) their content can be manipulated as needed; and (5) their membrane proteins allows their targeting
to precisely defined cell types, improving by engineering the specificity of any given treatment and,
thus, reducing the side effects.
Despite the range of available information about exosomes as potential disease biomarkers
and the increasing number of clinical trials on exosome-based drug delivery strategies, in cancer,
for example [191,192], comparatively little is known about exosomes in the CNS. Therefore, much
remains to be done to standardize the use of exosomes as therapeutic tools in CNS diseases.
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